
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Oligodendroglioma history and symptoms
Introduction
Overview
Overview
When evaluating a patient for oligodendroglioma, a detailed history of the presenting symptom (onset, duration, and progression), other associated symptoms, a thorough past medical history review, and review of common risk factors such as family history of brain tumors. Oligodendroglioma is a slow–growing, infiltrative tumor that may be clinically silent for many years. With tumor progression, symptoms may vary depending upon the location, size, and rate of tumor growth. Oligodendroglioma mainly involves the frontal lobe. Symptoms associated with oligodendroglioma include seizure, headache, nausea, vomiting, vertigo, visual loss, diplopia, strabismus, muscle weakness, numbness, speech difficulties, mood disturbances, personality changes, memory problems, low energy, fatigue, urge to sleep, loss of interest in daily activities, abulia, lack of spontaneity, loss of consciousness with syncope (few tonic-clonic jerks), and classic triad of headache, nausea, and papilledema due to raised intracranial pressure.
History
History
- While evaluating a patient for oligodendroglioma, a detailed history of the following should be taken:[1]
- Presenting symptom:
- Onset
- Duration
- Progression
- Other associated symptoms
- A thorough past medical history review
- Review of common risk factors such as:
- Presenting symptom:
Symptoms
Symptoms
- Oligodendroglioma is a slow-growing, infiltrative tumor that may be clinically silent for many years
- Asymptomatic patients are diagnosed based on incidental findings at the time of brain imaging performed for another reason (e.g: trauma, migraine headaches)
- Focal neurologic deficits and generalized symptoms such as headache are uncommon at the time of diagnosis
- With tumor progression, symptoms may vary depending on following characteristics of tumor:
- It mainly involves the frontal lobe
- Common symptoms associated with oligodendroglioma include:[2][3][4][5][6]
- Seizure (usually the first and most common presentation in 50-80% of the cases)[7]
- Headache
- Nausea
- Vomiting
- Vertigo
- Focal neurological deficits depending upon tumor location (symptoms usually caused by local tissue disruption, mass effect on nearby structures, or vasogenic edema) include:
- Cognitive dysfunction includes:
- Memory problems
- Changes in mood
- Changes in personality
- Low energy
- Fatigue
- Urge to sleep
- Loss of interest in daily activities
- Abulia (showing abnormal inability to act or make decisions)
- Lack of spontaneity
- Increased intracranial pressure (either due to a large mass or any restriction in cerebrospinal fluid outflow causing hydrocephalus) associated with following symptoms:
- Classic triad that includes:
- Loss of consciousness with syncope (maybe associated with a few tonic-clonic jerks)
| Tumor site of involvement | Clinical features |
|---|---|
| Frontal lobe |
|
| Temporal lobe |
References
References
- β McCarthy BJ, Rankin KM, Aldape K, Bondy ML, BrΓ€nnstrΓΆm T, Broholm H; et al. (2011). “Risk factors for oligodendroglial tumors: a pooled international study”. Neuro Oncol. 13 (2): 242β50. doi:10.1093/neuonc/noq173. PMCΒ 3064625. PMIDΒ 21149253.
- β Douay X, Daems-Monpeurt C, Labalette P, Blond S, Petit H (1997). “[Bilateral 3rd cranial nerve palsy disclosing oligodendroglioma]”. Rev Neurol (Paris). 153 (6β7): 430β2. PMIDΒ 9684012.
- β Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S; et al. (2007). “Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy”. Neurol Res. 29 (7): 723β6. doi:10.1179/016164107X208068. PMIDΒ 17553214.
- β Ogasawara H, Kiya K, Uozumi T, Sugiyama K, Kawamoto K, Ohta M (1990). “Multiple oligodendroglioma–case report”. Neurol Med Chir (Tokyo). 30 (2): 127β31. PMIDΒ 1695334.
- β Raciti-Daurio C, Caruso J (1990). “Oligodendroglioma–a case presentation”. Optom Vis Sci. 67 (1): 56β8. PMIDΒ 2308753.
- β Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B; et al. (2014). “Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients”. Am J Surg Pathol. 38 (8): 1058β70. doi:10.1097/PAS.0000000000000221. PMCΒ 4322928. PMIDΒ 24805856.
- β Cavaliere R, Farace E, Schiff D (2006). “Clinical implications of status epilepticus in patients with neoplasms”. Arch Neurol. 63 (12): 1746β9. doi:10.1001/archneur.63.12.1746. PMIDΒ 17172614.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
